Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
Fulgent Genetics (NASDAQ: FLGT), a technology-based company operating in laboratory services and therapeutic development, has scheduled its first quarter 2025 financial results announcement for Friday, May 2, 2025, before market opening.
The company will host an investment community conference call at 8:30 AM ET (5:30 AM PT) on the same day. Management will present the results and conduct a Q&A session. Investors can access the live audio webcast through the Investor Relations section of Fulgent's website, with an audio replay available afterward.
Fulgent Genetics (NASDAQ: FLGT), una società basata sulla tecnologia che opera nei servizi di laboratorio e nello sviluppo terapeutico, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per venerdì 2 maggio 2025, prima dell'apertura del mercato.
La società ospiterà una conferenza telefonica per la comunità degli investitori alle 8:30 AM ET (5:30 AM PT) dello stesso giorno. La direzione presenterà i risultati e condurrà una sessione di domande e risposte. Gli investitori possono accedere alla diretta audio tramite la sezione Relazioni con gli Investitori del sito web di Fulgent, con una registrazione audio disponibile successivamente.
Fulgent Genetics (NASDAQ: FLGT), una empresa basada en tecnología que opera en servicios de laboratorio y desarrollo terapéutico, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para viernes 2 de mayo de 2025, antes de la apertura del mercado.
La empresa llevará a cabo una conferencia telefónica para la comunidad inversora a las 8:30 AM ET (5:30 AM PT) el mismo día. La dirección presentará los resultados y realizará una sesión de preguntas y respuestas. Los inversores pueden acceder a la transmisión de audio en vivo a través de la sección de Relaciones con Inversores del sitio web de Fulgent, con una repetición de audio disponible después.
풀젠트 유전자(Fulgent Genetics, NASDAQ: FLGT)는 실험실 서비스와 치료 개발을 운영하는 기술 기반 회사로, 2025년 5월 2일 금요일에 2025년 1분기 재무 결과 발표를 예정하고 있습니다. 시장 개장 전에 발표됩니다.
회사는 같은 날 오전 8:30 ET (오전 5:30 PT)에 투자자 커뮤니티를 위한 전화 회의를 개최합니다. 경영진은 결과를 발표하고 Q&A 세션을 진행할 것입니다. 투자자들은 풀젠트 웹사이트의 투자자 관계 섹션을 통해 라이브 오디오 웹캐스트에 접속할 수 있으며, 이후 오디오 재생도 가능합니다.
Fulgent Genetics (NASDAQ: FLGT), une entreprise technologique opérant dans les services de laboratoire et le développement thérapeutique, a prévu l'annonce de ses résultats financiers du premier trimestre 2025 pour vendredi 2 mai 2025, avant l'ouverture du marché.
L'entreprise organisera une conférence téléphonique pour la communauté des investisseurs à 8h30 ET (5h30 PT) le même jour. La direction présentera les résultats et animera une session de questions-réponses. Les investisseurs peuvent accéder à la diffusion audio en direct via la section Relations Investisseurs du site web de Fulgent, avec une rediffusion audio disponible par la suite.
Fulgent Genetics (NASDAQ: FLGT), ein technologieorientiertes Unternehmen, das im Bereich Laborservices und therapeutische Entwicklung tätig ist, hat die Bekanntgabe der finanziellen Ergebnisse für das erste Quartal 2025 auf Freitag, den 2. Mai 2025, vor Markteröffnung angesetzt.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz für die Investment-Community abhalten. Das Management wird die Ergebnisse vorstellen und eine Frage-Antwort-Runde durchführen. Investoren können über den Bereich Investor Relations auf der Website von Fulgent auf den Live-Audio-Webcast zugreifen, und eine Audio-Wiedergabe wird danach verfügbar sein.
- None.
- None.
The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250410967484/en/
Investor Relations Contact:
The Blueshirt Group
Melanie Solomon, melanie@blueshirtgroup.com
Source: Fulgent Genetics, Inc.
FAQ
When will Fulgent Genetics (FLGT) release Q1 2025 earnings?
What time is Fulgent's (FLGT) Q1 2025 earnings call?
How can investors access Fulgent's (FLGT) Q1 2025 earnings call?
Will there be a replay available for Fulgent's (FLGT) Q1 2025 earnings call?
